A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)

Trial Profile

A Phase 1 Multicenter Open Label Safety and Tolerability Clinical Trial of Ciliary Neurotrophic Factor (CNTF) in Patients With Macular Telangiectasia Type 2 (Mactel)

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2016

At a glance

  • Drugs NT 501 (Primary)
  • Indications Retinal telangiectasis
  • Focus Therapeutic Use
  • Sponsors GNT Pharma
  • Most Recent Events

    • 21 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2015 Planned End Date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
    • 23 Feb 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Sep 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top